Mizuho Bullish on Horizon Pharma (HZNP) Into Today's Investor Day
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500, Dow rise on Mideast deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- BofA lifts targets on AMD and ARM, raises CPU TAM to $170bn
Actimmune and Friedreich's Ataxia Could Help Horizon Pharma (HZNP) Post Upside, Mizuho Says; PT to $34
November 10, 2015 6:57 AM ESTHorizon Pharma (NASDAQ: HZNP) reported 3Q:15 revenue of $226.5M vs. consensus of $193.2M. Adjusted EPS of $0.70 also beat the consensus number of $0.41. The beat was driven by strong product demand (volumes) across all of the company's brands, coupled with lower than expected SG&A expense and... More
Horizon Pharma (HZNP) Tops Q3 EPS by 30c; Boosts FY15 Revenue Outlook
November 6, 2015 7:01 AM ESTHorizon Pharma (NASDAQ: HZNP) reported Q3 EPS of $0.70, $0.30 better than the analyst estimate of $0.40. Revenue for the quarter came in at $292.7 million versus the consensus estimate of $185.7 million.
Horizon Pharma sees FY2015 revenue of $750-760 million, versus prior guidance of $660-680 million and the... More
